US won’t back 2022 patent waivers for Covid tests and treatments
The US joins nearly three dozen nations in seeking more time and information about a potential waiver extension.
By Bryce Baschuk, bloomberg
The US won’t agree to waive intellectual property protections for Covid-19 treatments and tests this year - aligning it with developed nation peers and delaying prospects for a World Trade Organization accord aimed at boosting global access to life-saving medicines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Amgen hails cost-saving effect of biosimilars
For subscribers
